Two injections a year. That’s all it takes to protect against HIV with lenacapavir, a revolutionary drug hailed as potentially the beginning of the end of the epidemic, but its rollout has been slow. It has efficacy close to 100% and is already being distributed in small quantities in nine priority African countries. In middle-income countries such as those in Latin America it has not yet arrived, despite the fact that their residents took part in the clinical trials. The international HIV/AIDS conference held in Rio de Janeiro a few days ago was marked by protests against the pharmaceutical company that developed the drug and which, for now, holds the global monopoly: the U.S. firm Gilead Sciences.
Seguir leyendo